Palbociclib Might Reverse Acquired Breast Cancer Endocrine Resistance

Palbociclib alone and in combination with endocrine therapy offers clinical benefit among women with HR-positive, HER2-negative metastatic breast cancer.

Source: CancerNetwork - June 4, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Conferences/ASCO Breast Cancer News Source Type: news